TurboWorx Software Dramatically Increases MDS Proteomics’ Ability to Conduct Data Analysis and Interpretation
Burlington, MA, USA and Toronto, Ontario, CANADA — February 17, 2004 — MDS Proteomics, Inc. announced it has purchased and deployed TurboWorx software to achieve significant improvements in the automation and acceleration of analytical processing workflows and processes integrating disparate data and applications. MDSP is the leading proteomics-based drug discovery and development company that has developed novel proteomic approaches to better understand the underlying molecular causes of disease and drug action. TurboWorx provides integrated, end-to-end solutions for creating, managing and accelerating compute- and data-intensive applications and workflows in heterogeneous distributed computing environments and grids.
“As we evaluated technology solutions, it quickly became clear that TurboWorx’ open, standards-based products best matched our business priorities– low cost of ownership, rapid deployment, and return-on-investment,” said Thodoros Topaloglou, Sr. Vice President of Scientific Computing and IT at MDS Proteomics, Inc. “As a result, TurboWorx has provided us with an invaluable technical solution that automates the creation and execution of complex workflows in our mixed compute environment,” Topaloglou added.
“MDS Proteomics’ adoption of our software marks a significant milestone in the evolution of research and development in the life sciences field,” said Jeff Augen, President and CEO, TurboWorx, Inc. “TurboWorx creates a competitive advantage for its customers by allowing them to automate complex projects composed of large numbers of individual applications. Our software is a true source of value creation because it optimizes the use of computer hardware,” said Augen. “These advantages extend to heterogeneous environments containing a mix of operating systems and dissimilar hardware. This allows companies to re-focus their resources on core scientific or business activities and devote less effort to programming,” Augen concluded.
Leading analysts and companies in all verticals are quickly realizing that TurboWorx provides the only solution that enables firms to easily and quickly wrap proprietary and third-party applications into components that become parts of workflows that can be executed across heterogeneous computing environments. As a result, TurboWorx is experiencing tremendous demand for its solutions not only in life science research, but also in many other industries, including financial services, process manufacturing, automotive, energy exploration and production, aerospace, and information-based medicine.
TurboWorx also provides business benefits by improving performance of compute-intensive applications that run too slowly, allowing them to be distributed across a diverse high-performance computing environment. The company’s solutions capture unused cycles from networked compute servers and integrate diverse applications into workflows that deliver improved performance for complex processes.
# # #
About TurboWorx, Inc.
TurboWorx provides integrated, end-to-end solutions for creating, managing and accelerating compute- and data-intensive applications and workflows in heterogeneous distributed computing environments and grids. TurboWorx’ open, standards-based products leverage SmartGrid™ technology to deliver order-of-magnitude improvements in the automation and acceleration of collaborative workflows and processes across disparate data and applications, leading to substantial return on investment for the enterprise, its customers and partners. The unique SmartGrid technology enables: creation and management of complex workflows and integration of diverse applications and data; intelligent routing of data and applications to unused compute resources; delivery of results at light speed without requiring end-users to know which servers run their applications and where their data physically reside; execution of distributed workflows in heterogeneous computing environments and grids; and uncompromised flexibility for Power Users while allowing IT organizations to maintain control over enterprise resources.
For more information, visit www.turboworx.com or contact Joe Romano, Partner, HighGround, Inc. at 781-279-1320 x 208 or jromano@highgroundinc.com.
About MDS Proteomics, Inc.
MDS Proteomics, Inc. (‘MDSP’) is a drug discovery and development company that has developed novel proteomic approaches to better understand the underlying molecular causes of disease and drug action. The company is applying these methods in an integrated fashion for the purpose of developing more potent and selective therapeutics. MDSP has its headquarters in Toronto, and research operations in Toronto, Ontario, Canada and Charlottesville, Virginia, U.S.A. MDS Proteomics is a private company that is majority-owned by MDS, Inc. For more information on MDS Proteomics, visit www.mdsp.com.
About MDS, Inc.
MDS, Inc. (NYSE:MDZ; TSX:MDS) is an international health and life sciences company. Its products and services include: laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research and clinical development services for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people at its global operations on four continents. Detailed information about the company is available at the MDS website at http://www.mdsintl.com/.
